Shares of Total System Services, Inc. (NYSE: TSS) were trading down about 8 percent in Tuesday’s after-hours session, following the announcement of the company’s fourth quarter fiscal 2015 financial results. The global payment solutions provider reported earnings of $0.57 per share, $0.03 below consensus, on revenue of $$716.8 million – up 12.9 percent year-over-year, and above the Street’s estimate of $688.94 million.
Another big decliner was Lannett Company, Inc. (NYSE: LCI), down more than 7.4 percent after the bell rang. The tumble was prompted by the preannouncement of the company’s second quarter fiscal 2016 financial results. Management now expects net sales of approximately $127 million, GAAP earnings per diluted share of $0.33 to $0.36 and adjusted earnings per diluted share of $0.93 to $0.95. These results compare to last year’s net sales of $114.8 million, GAAP earnings of $1.21 per diluted share, and adjusted EPS of $1.24.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Fate Therapeutics Inc (NASDAQ: FATE) was up almost 17 percent after the market closed.
The surge was triggered by the announcement that the U.S. Food and Drug Administration has cleared the biopharmaceutical company’s “investigational new drug (IND) application for ProTmune™, a programmed cellular immunotherapy consisting of donor-sourced mobilized peripheral blood cells which have been functionally modulated using two small molecules. The IND is now active and Fate Therapeutics plans to initiate a multi-center, randomized, controlled Phase 1/2 clinical trial in adult patients with hematologic malignancies undergoing mobilized peripheral blood (mPB) hematopoietic cell transplantation (HCT) in mid-2016."
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.